Judson Englert, M.D., Ph.D.
SVP, Clinical Research & Development

Dr. Englert is a board-certified medical oncologist and physician-scientist with a proven track record in drug development both in the pharmaceutical industry and academia. Dr. Englert served in a leading role in early clinical development of immune-oncology drugs as director of Clinical Development, Oncology, at AstraZeneca/Medimmune. Prior to joining Cyteir, Dr. Englert served as senior director of Translational Sciences at UPMC Enterprises. He holds a PhD in Cellular and Molecular Pathology and an MD from the University of Pittsburgh School of Medicine. Dr. Englert trained in Internal Medicine at the Brigham & Women’s Hospital at Harvard University and completed his medical oncology training at Johns Hopkins University.